talent pool executive appointments and promotions in the healthcare industry Pharmaceutical POOL Dr. Ann MILLER Steven SEMBLER Eisai Appoints Two Senior VPs Eisai Inc. has expanded its leadership roster with the hiring of two senior VPs. Ann Miller, M.D., joins Eisai as senior VP, primary care and specialty business unit. Dr. Miller has more than 20 years of experience in the biopharmaceutical industry, with leadership roles at companies such as Amgen and Merck. Before joining Eisai, she was engaged in commercialization and marketing consulting. Dr. Miller received an M.D. from Duke University School of Medicine, with membership in Alpha Omega Alpha, the medical honor society. In other moves, Eisai has named Steven Sembler senior VP, oncology and institutional care, where he is responsible for all aspects of the U.S commercial business for the oncology and institutional care therapeutic arenas. Most recently he served as Roche’s VP, specialty care commercial operations. Biotechnology POOL Kenneth MOCH Chimerix Appoints First Operating Chief Chimerix, a biotechnology company developing orally available antiviral therapeutics, has named Kenneth Moch to the newly created position of chief operating officer. Mr. Moch brings to Chimerix more than 25 years of experience in managing and financing biomedical technologies and has played a key role in building several life-sciences companies. Before joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors. He received an MBA from the Stanford Graduate School of Business. Dr. Mark ROLFE Facet Taps Millennium Veteran as Scientific Chief Oncology-focused Facet Biotech has appointed Mark Rolfe, Ph.D., senior VP and chief scientific officer. He is responsible for leading the company’s research efforts, including target validation, translational medicine, and protein engineering technologies. Dr. Rolfe joins Facet after a decade at Millennium: The Takeda Oncology Company, where he most recently served as VP, oncology discovery. He earned a Ph.D. from the National Institute for Medical Research, London, and an M.A. from the University of Oxford’s Brasenose College. Biopharmaceutical POOL Scott BYRD Lilly Veteran Joins Cadence as Commercial Chief Cadence Pharmaceuticals has named Scott Byrd senior VP and chief commercial officer, with responsibility for sales, marketing, and supply operations. Cadence is a biopharmaceutical company focused on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting. Mr. Byrd joins Cadence after 17 years at Eli Lilly, where he was most recently U.S. brand leader, Prasugrel. He holds an MBA from Harvard Business School. Paulette DILLON Dr. Tito SERAFINI Nuon Adds Business, Scientific Chiefs Nuon Therapeutics, a clinical stage, privately held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, has named Paulette Dillon chief business officer. Ms. Dillon joins Nuon Therapeutics from Anacor Pharmaceuticals, where she was chief business officer. The company also has appointed Tito Serafini, Ph.D., as chief scientific officer. Dr. Serafini joins Nuon Therapeutics from Renovis, where he was a co-founder. He received a Ph.D. in biochemistry from Stanford University and was a postdoctoral fellow at the University of California, San Francisco. Dr. Lorianne MASUOKA Nektar Therapeutics Promotes Medical Chief Nektar Therapeutics, a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has promoted Lorianne Masuoka, M.D., to chief medical officer from VP of clinical development. She received an M.D. from the University of California, Davis, completed a fellowship at Yale University, and is board-certified in neurology. Dr. H. Michael SHEPARD Pioneering Researcher Joins Halozyme as Discovery VP Halozyme Therapeutics, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, has named H. Michael Shepard, Ph.D., VP, discovery research. During his 25-year career, Dr. Shepard has been a recipient of numerous biotechnology patents and scientific awards for his contributions to the development of innovative therapies. Most recently, he served as founder and president of Receptor BioLogix. Dr. Shepard received a Ph.D. in molecular, cellular, and developmental biology from Indiana University, where he was a Damon Runyon Cancer Research Foundation Fellow. Emerging POOL Duncan HIGGONS Dr. David SCHENKEIN Agios Pharmaceuticals Establishes Leadership Team Agios Pharmaceuticals has announced the creation of an executive leadership team as it enters the next stage of its development as a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism. Duncan Higgons has joined Agios as chief operating officer from Archemix, where he served as chief operating officer, president, and interim CEO. He received an M.Sc. (Econ) from London Business School. David Schenkein, M.D., has been named CEO of Agios, succeeding interim CEO Kevin Starr, partner, Third Rock Ventures. Dr. Schenkein was most recently senior VP, clinical hematology/oncology, for Genentech. He received an M.D. from the State University of New York Upstate Medical School. Agency POOL Donald BROGAN Lorna WEIR Vox Medica Strengthens Leadership Team Independent healthcare communications company Vox Medica has added two executives to its leadership team. Donald Brogan has rejoined Vox as senior VP/practice leader, education and adult learning. Mr. Brogan leads the team of training, promotional education, and event practitioners and oversees the in-house speakers’ bureau. Mr. Brogan was most recently VP and director of Jack Morton Healthcare. Vox also has named Lorna Weir to the newly created position of executive VP/chief marketing strategist. Ms. Weir is responsible for working with Vox clients to discover brand-building opportunities and lead strategic marketing program development, as well as overseeing Vox’s PEER proprietary method. Previously, Ms. Weir was president of Dudnyk. She is a graduate of the University of Maine School of Law and was admitted to the Bar of Pennsylvania. Don MARTINY Former Dorland Creative Chief Joins Altum Altum, a CommonHealth full-service professional advertising and promotion company, has appointed Don Martiny executive VP, chief creative officer. Mr. Martiny is directly responsible for the overall management and productivity of the Altum creative team, as well as assisting with client relationship-building and new business development for the Altum group. Most recently, Mr. Martiny served as executive VP, chief creative officer, for Dorland Global. Sherry MILLER Jesus SANCHEZ Jr. Jason VERBICK AbelsonTaylor Announces Staff Moves Independent healthcare advertising agency AbelsonTaylor has announced two promotions and one new hire on the creative side. Sherry Miller has been promoted to senior art production artist from art production artist, with responsibility for working on a wide range of products. Jesus Sanchez Jr. has been promoted to art director from associate art director and is working on a cardiovascular product. Jason Verbick has joined AbelsonTaylor as senior copywriter from Palio Communications, where he served as group copy supervisor. Richard PATTERSON MicroMass Names Group Account Director MicroMass Communications has appointed Richard Patterson VP, group account director, with responsibility for spearheading the agency’s oncology business. With almost three decades of healthcare marketing experience, Mr. Patterson joins MicroMass from Patterson Consulting Group, which he founded in 2003 and led as president. He holds an M.S. in biological chemistry and an M.S. in human genetics, both from the University of Michigan. Pamela PINTA New Director of Client Services at Flaum Communications Pamela Pinta has been named director of client services for Flaum Communications, a full-service healthcare marketing division of Flaum Partners. Ms. Pinta was previously managing director for Euro RSCG Life Chelsea. Consulting POOL David LILLEY Jon MCGARITY Campbell Alliance Adds Two Executive VPs Campbell Alliance has appointed industry veterans David Lilley and Jon McGarity as executive VPs, with responsibility for advising the firm’s emerging and midsize client companies. With more than 30 years of pharmaceutical and biotechnology industry experience, Mr. Lilley most recently led the commercial arm of Quintiles investment unit NovaQuest. Mr. McGarity’s career in pharmaceutical and biotechnology spans more than four decades, and he most recently served as president and CEO of EthiX Associates. CRO POOL Becky CAUSEY ResearchPoint Hires Clinical Operations VP Global CRO ResearchPoint has appointed Becky Causey VP of clinical operations. Ms. Causey oversees ResearchPoint’s clinical operations, project management, and monitoring groups and works closely with the executive team to define processes and strategic direction for operations. Medical Education POOL Jaclyn BURKART Laine CAPACCIO Patrick DONNELLY Dr. Jonathan KAMIEN Catherine KITTO Gregg MACHAK Dr. Michael PUCCI Dr. Greg TARDIE HLS Continues Growth HLS, the medical-education unit of CommonHealth, has announced a number of promotions and new hires. Jaclyn Burkart has advanced to account director from account manager. Ms. Burkart has been with HLS for five years. Laine Capaccio has been named publications director. Ms. Capaccio joins HLS from Warner Chilcott, where she was a pharmaceutical sales representative specializing in obstetrics and gynecological products. Patrick Donnelly has been hired as an account manager. Mr. Donnelly was previously a project manager at M2 Communications. Jonathan Kamien, Ph.D., has joined HLS as a senior medical director. He most recently served as a scientific director for SynerMed. Dr. Kamien holds a Ph.D. in biopsychology. HLS has hired Catherine Kitto as editorial director. Most recently, Ms. Kitto worked as editorial director at Concentric Pharma Advertising. Gregg Machak, a 20-year HLS veteran, has been elevated to senior VP, coordination, production and digital services from his previous post of senior VP, creative services. Additionally, he has been named the healthcare compliance officer for HLS. Michael Pucci, Ph.D., has been promoted to senior medical director from medical director. Dr. Pucci holds a Ph.D. in pharmacology. Greg Tardie, Ph.D., has joined HLS as a medical director. Dr. Tardie was previously a scientific director at Cerebrio. Dr. Tardie has a Ph.D. in exercise physiology. Service POOL Rod ANAFORIAN Kim FOSTER Mark GROVE Dean KLEYN Qforma Expands Sales, Field Operations Groups Qforma, an advanced analytics and predictive modeling company, has appointed four executives to its sales and field operations teams. Rod Anaforian and Kim Foster have joined Qforma as directors, field operations. Mr. Anaforian has 25 years of experience in pharmaceutical sales, sales training, and field sales management. Ms. Foster most recently worked as an independent contractor on data analysis and programming projects for ArcLight Systems. Mark Grove has been appointed senior VP, sales, new business. Mr. Grove joins Qforma from Healthy Advice Networks, where he served as executive VP. Dean Kleyn has been promoted to VP, sales and services, from director, field operations. Nikki FINK MMG Hires Patient Recruitment Veteran Full-service patient recruitment and retention group MMG has appointed Nikki Fink senior strategist and VP of general medicine. Most recently, she led the patient recruitment and site efforts at Array BioPharma. Vernon GRUBISICH Fact Flow Research Hires Senior Director Full-service market research group Fact Flow Research, a business unit of Purohit Navigation, has named Vernon Grubisich senior research director. Mr. Grubisich most recently worked as a manager of qualitative services and senior consultant for two healthcare market research firms: Ziment and Irvine Consulting. Technology POOL Scipio (Max) CARNECCHIA Accelrys Names CEO Accelrys, a global provider of scientific business intelligence software and services, has appointed Scipio (Max) Carnecchia CEO and president. Mr. Carnecchia succeeds Todd Johnson, who has served as interim CEO and president since January. Mr. Carnecchia has more than two decades of experience, most recently as president of Interwoven. Diana (Dee) PEARSON PHT Selects Global Partnerships Director Diana (Dee) Pearson has rejoined PHT, a provider of electronic patient reported outcome (ePRO) solutions used in clinical trials, as director of global partnerships. She received an M.A. in experimental psychology from Kent State University. F Send your personnel announcements to [email protected]. Biotechnology POOL Jeffrey JANUS Dr. Andrei SEMETCHKINE ISCO Announces Leadership Shift in Preparation for Expansion International Stem Cell Corporation (ISCO) has expanded its senior management team to include greater capacity and flexibility as it widens its therapeutic and commercial activities for the remainder of 2009 and beyond. ISCO is a biotechnology company focused on developing therapeutic and research products through technology that results in the creation of pluripotent human stem cell lines from unfertilized human eggs. Jeffrey Janus, CEO and president of ISCO subsidiary Lifeline Cell Technology, has been named to the additional role of senior VP of operations for ISCO. Andrei Semetchkine, Ph.D., already a director and officer of ISCO, has assumed the duties of executive VP of the company, with broad responsibility for the strategy, financial, and business affairs of the company. Dr. Semetchkine is a longstanding member of the Russian Academy of Sciences, the highest scientific body in Russia. Sunil PATEL New Corporate Development VP at OncoMed OncoMed Pharmaceuticals, a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, has named Sunil Patel senior VP, corporate development. Mr. Patel joins OncoMed from BiPar Sciences, as VP, corporate development and marketing. He led the sale of BiPar to Sanofi-Aventis in April 2009. He has a master’s degree in molecular bioengineering/biotechnology from the University of Washington. Biopharmaceutical POOL Richard BREWER Dr. Michael BRISTOW ARCA Leaders Swap Roles ARCA Biopharma, a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, has announced a leadership change to reflect the company’s recent shift in strategy to seek alternatives for the potential commercialization of Gencaro. Richard Brewer has resigned as CEO and assumed the role of chairman. Mr. Brewer has been with ARCA since November 2006; he holds an MBA from Northwestern University. In addition, ARCA Co-founder Michael Bristow, M.D., Ph.D., has stepped down as chairman and taken on the role of president and CEO, which he had previously held from the company’s inception in September 2004 to November 2006. Most recently, Dr. Bristow served as ARCA’s chief science and medical officer. In addition to his duties at ARCA, he is a professor of medicine and the former head of cardiology at the University of Colorado Health Sciences Center. David MADDEN Dicerna Announces New Chairman Dicerna Pharmaceuticals has named pharmaceutical industry veteran David Madden as chairman. He succeeds Douglas Fambrough, Ph.D., general partner with Oxford Biosciences Partners, who remains a board member. Mr. Madden was most recently interim CEO for Adolor and currently serves as chairman of its board. He received an MBA from Columbia University. Dicerna is a second-generation RNA interference (RNAi) company developing novel therapeutics using its proprietary Dicer Substrate Technology and dicer substrate RNA (DsiRNA) molecules. Specialty POOL Glenn DAVIS ISTA Pharmaceuticals Names Compliance Chief Ophthalmic pharmaceutical company ISTA Pharmaceuticals has hired Glenn Davis, J.D., as VP, legal and chief compliance officer. Mr. Davis has more than 35 years experience in the practice of food and drug law, and he was most recently in solo practice erving life-sciences clients. He received a J.D. from Boalt Hall School of Law, University of California, Berkeley. Drug Delivery POOL Robert APPLE Dr. Kaushik DAVE Dr. Peter SADOWSKI Antares Pharma Promotes Three VPs Antares Pharma, a product development company committed to improving pharmaceuticals through its patented drug-delivery systems, has announced three promotions among its executive team. Robert Apple has been elevated to executive VP, chief financial officer, and president of the parenteral products division. Mr. Apple joined Antares in February 2006 as senior VP and chief financial officer. Kaushik Dave, Ph.D., has been promoted to senior VP, product development, from VP, clinical and regulatory affairs. Dr. Dave received a Ph.D. in pharmaceutical chemistry from the University of Kansas and an MBA from the Wharton School of the University of Pennsylvania. Antares also has promoted Peter Sadowski, Ph.D., to senior VP of the parenteral products division from VP, product development. He holds a Ph.D. in microbiology from the University of Minnesota. Emerging POOL Dr. James FRINCKE Dr. Christopher READING Hollis-Eden Promotes Scientific Chief to CEO Hollis-Eden Pharmaceuticals, a developer of a new class of small molecule compounds based on endogenous adrenal steroid hormones, has named James Frincke, Ph.D., president and CEO. Dr. Frincke first joined Hollis-Eden in 1997 as VP, research and development, and he has served as chief scientific officer since 2001. He received a Ph.D. in chemistry from the University of California, Davis, and completed postdoctoral work at the University of California, San Diego. Dr. Frincke is succeeded as chief scientific officer by Christopher Reading, Ph.D., former executive VP, scientific development, at Hollis-Eden. Dr. Reading earned a Ph.D. in biochemistry from the University of California, Berkeley, and completed postdoctoral study in tumor biology at the University of California, Irvine. Association POOL Jonathan ANDRUS DIA Elects BioClinica VP as E-clinical Chair Jonathan Andrus, VP, clinical data management and regulatory operations at BioClinica’s e-clinical service division, has been elected as the Drug Information Association (DIA) North American Special Interest Area Communities (SIAC) e-clinical chair. The SIACs provide a forum for volunteers to network and exchange information within the pharmaceutical industry and assist DIA in identifying professional development needs in particular interest areas. They also provide information to members in career and professional development and promote education, training, and development of professionals in the biopharmaceutical and healthcare industries. Mr. Andrus has an M.S. in quality assurance and regulatory affairs from Temple University’s Graduate School of Pharmacy and is a certified quality auditor and certified clinical data manager. Other professional affiliations include the Society for Clinical Data Management, the American Society for Quality, and the Mid-Atlantic Region Society for Quality Assurance. He is also an instructor with the Pharmaceutical Training Institute. Les JORDAN Microsoft Strategist Tapped to Lead BioIT Alliance Les Jordan, industry chief technology strategist, U.S. Health and Life Sciences Group, Microsoft, has been named director of the BioIT Alliance, a group of organizations working together to realize personalized medicine. Mr. Jordan’s focus is to create a board of directors and lead the BioIT Alliance toward a more independent model that allows for better objectivity and a greater ability to tackle industry problems. Mr. Jordan has more than 15 years of industry experience setting technical direction and strategy. In his current position at Microsoft, he provides architectural, technical, and industry-specific guidance to internal product teams, partner companies, and Microsoft’s largest pharmaceutical and health products enterprise customers. Agency POOL Mark ALLEN Brooke BARRIER Christina BLOSSER Meghan CAREY Galo ERAZO Tera HARMON Cara KAPUT David MARTIN GSW Worldwide Makes Staff Changes Healthcare advertising agency GSW Worldwide, an inVentiv Health company, has announced a number of new appointments at its locations in Ohio and New York. In New York, Mark Allen has been named VP, associate creative director. Mr. Allen was most recently VP, creative director, for Digitas Health. Brooke Barrier has been appointed copy supervisor for the New York office. Before joining GSW, Ms. Barrier was senior copywriter for DraftFCB Healthcare. She holds a master’s degree from Medill School of Journalism at Northwestern University. Christina Blosser has joined the New York office as senior VP, new business development. Previously, Ms. Blosser worked at DraftFCB Healthcare as VP, group account supervisor. Also in New York, Meghan Carey has been appointed senior art director. Ms. Carey was most recently art director for DraftFCB Healthcare. Galo Erazo has been named VP, associate creative director, in New York. Mr. Erazo previously was VP, associative creative director, for Ogilvy Healthcare. Tera Harmon has joined GSW’s Columbus, Ohio, office as senior editor. Ms. Harmon most recently worked for The McGraw-Hill Companies as project leader. Also in Columbus, Cara Kaput has been named medical writer. Most recently, Ms. Kaput held an internship at Meijer Pharmacy. She received a doctorate from The Ohio State University. In New York, David Martin has been named account director. Before GSW, Mr. Martin served as account supervisor for KPR. Kerry AUBIN Dana ENNIS Nancy LONSINGER Andrea Heslin SMILEY VMS Bolsters Management VMS has added four top industry executives to help provide strategic direction as the biomarketing company seeks to expand its marketing support and solutions offerings for clients in the life-sciences and healthcare industries. As part of this shift, VMS has altered the company name from Virtual Meeting Strategies to Virtual Marketing Strategies. As part of reinventing the brand, VMS has also developed a communications platform to better articulate its value proposition. As VP of client services, Kerry Aubin plays an instrumental role in driving strategic planning and program development for VMS clients. Ms. Aubin has more than a decade of experience in marketing and sales for pharmaceutical and highly regulated international businesses, including Eli Lilly, where she held various roles in marketing, sales, and finance and developed strategic marketing programs for osteoporosis therapeutics. Dana Ennis brings 15 years of sales and marketing experience at companies such as Merck and GlaxoSmithKline to his role as VP of sales and corporate development. Mr. Ennis is responsible for driving new business efforts for VMS and offering clients counsel on sales-related initiatives. Nancy Lonsinger serves as VP of strategy and chief compliance officer, driving strategic planning and compliance programs for clients in bio-related industries. Ms. Lonsinger has more than 20 years of experience as a business leader with extensive experience in marketing and sales for healthcare and consumer brands, most recently as VP of consumer marketing for Polymer Technology Systems. She earned an MBA in marketing from Indiana University. As senior VP of strategic marketing and client services, Andrea Heslin Smiley is responsible for leading VMS’ strategic marketing and brand development business groups. Before joining the agency, Ms. Smiley spent 18 years in the pharmaceutical industry, including a stint as the leader of Eli Lilly’s osteoporosis business unit. She completed the Harvard Executive Business Program in 2005 and is certified as a Black Belt in the Six Sigma process. Jairaj MASHRU Layne SHAPIRO Stinson Expands Account Team Stinson Brand Innovation, a global health, science, and technology brand consultancy, has added Jairaj Mashru and Layne Shapiro as account executives. Both Mr. Mashru and Ms. Shapiro are taking lead roles on client projects in several rare disease categories. Mr. Mashru has an MBA in international management from the Thunderbird School of Global Management. Ms. Shapiro joins Stinson from Young Innovations, where she served as a business development specialist. She received an MBA from National-Louis University. CRO POOL Dr. Lars-Olof ERIKSSON Parexel Appoints VP to Head Recruitment Team Global biopharmaceutical services provider Parexel International has named Lars-Olof Eriksson, Ph.D., MS.c., VP of its Start-up and Accelerated Recruitment Team (START). Dr. Eriksson leads a global team of Parexel experts in providing a strategic, comprehensive approach to accelerate study initiation and achieve last-patient-in (LPI) milestones for Parexel’s regional and international clinical trials. He joins Parexel from Merck, where he served as a senior director in clinical research operations specializing in patient recruitment. Dr. Steven MICHAEL Former Pfizer Director Joins Covance Global drug-development services company Covance has named Steven Michael, Ph.D., VP and chief scientific officer of global bioanalytical services, with responsibility for leading scientific, marketing, and business development strategy in this area. Dr. Michael has 15 years of experience in bioanalytical research, translational research, and talent development, most recently at Pfizer Global Research and Development, where he served as executive director of bioanalytical research in worldwide pharmacokinetics, dynamics, and metabolism. He received a doctorate in analytical chemistry from the University of Michigan. Service POOL Dr. Mike JOHNSRUD Dr. Erin SULLIVAN Avalere Health Expands Research Capabilities Avalere Health has expanded its health economics and outcomes research capabilities with the addition of two senior experts in the field. Mike Johnsrud, Ph.D., brings to Avalere a wealth of experience in analyzing drug utilization trends, as well as deep knowledge of prescription reimbursement policy in Medicaid, Medicare, and private-sector plans. A registered pharmacist, Dr. Johnsrud was most recently associate director of the Center for Pharmacoeconomic Studies at the University of Texas at Austin. Erin Sullivan, Ph.D., MPH, joins Avalere from Abt BioPharma Solutions, where she was a senior director in the health economic research and quality-of-life evaluation services division. Dr. Sullivan has directed and published research on incorporating patient-reported outcomes into medical device trials, modeling the cost-effectiveness of various health technologies and performing health economic studies using secondary databases. John LAHAYE Steve LEONARD Catalent Adds to Commercial Packaging, Global Operations Teams John LaHaye has joined Catalent Pharma Solutions as VP of business development for the commercial packaging business of Catalent’s packaging services segment. Mr. LaHaye has responsibility for the U.S. commercial packaging salesforce. Most recently he was with Sentrx, where he was executive VP of business development. In other moves, Catalent has appointed Steve Leonard senior VP of global operations. Mr. Leonard joins Catalent after 22 years at GE, where he most recently served as general manager of global operations for GE Healthcare’s global medical diagnostics business. Catalent provides advanced dose form and packaging technologies and development, manufacturing, and packaging services for pharmaceutical, biotechnology, and consumer healthcare companies. Michael SMYTH TransPerfect Selects Life-Sciences Solutions Manager TransPerfect, a provider of language services and solutions to the life-sciences industry, has named Michael Smyth general manager of its Life Sciences Solutions division. Mr. Smyth brings to TransPerfect more than 17 years of experience in clinical development for Merck and Quintiles, and most recently, he served as VP, trial management solutions, with Perceptive Informatics (formerly ClinPhone). F

Download PDF